Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Hoepner

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
European Journal of Neurology|November 28, 2022
Anti-neurochondrin antibody as a biomarker in primary autoimmune cerebellar ataxia-a case report and review of the literatureAnina Schwarzwald, Anke Salmen, Alejandro Xavier León Betancourt, et al.
European Journal of Neurology|February 23, 2023
Anti-kelchlike protein 11 antibody-associated encephalitis: Two case reports and review of the literatureAlejandro León Betancourt, Anina Schwarzwald, Alban Millonig, et al.
CNS Neuroscience & Therapeutics|August 17, 2022
Multidimensional phenotyping of the post-COVID-19 syndrome: A Swiss survey studyLara Diem, Anina Schwarzwald, Christoph Friedli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 6, 2025
Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?Gabriel Bsteh, Stefanie Marti, Helly Hammer, et al.
Acta Neuropathologica Communications|June 18, 2026
Higher disease reactivation risk in women after fingolimod withdrawalMarine Massy, Stefanie Marti, Adriane Kutllovci, et al.
Journal of Central Nervous System Disease|May 7, 2024
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational studyChristoph Friedli, Nik Krajnc, Helly N Hammer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 8, 2016
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathyRobert Hoepner, Eva M Kolb, Stefanie Dahlhaus, et al.
Multiple Sclerosis and Related Disorders|December 11, 2024
Disability progression is a question of definition-A methodological reappraisal by example of primary progressive multiple sclerosisGabriel Bsteh, Stefanie Marti, Nik Krajnc, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2021
Different Fumaric Acid Esters Elicit Distinct Pharmacologic ResponsesBrian T Wipke, Robert Hoepner, Katrin Strassburger-Krogias, et al.
Frontiers in Digital Health|June 15, 2026
Listening to MS: AI-assisted speech analysis for diagnosis and fatigue prediction (COMMITMENT)Helly Hammer, Monica Gonzalez-Machorro, Pascal Hecker, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
European Journal of Neurology|November 28, 2022
Anti-neurochondrin antibody as a biomarker in primary autoimmune cerebellar ataxia-a case report and review of the literatureAnina Schwarzwald, Anke Salmen, Alejandro Xavier León Betancourt, et al.
European Journal of Neurology|February 23, 2023
Anti-kelchlike protein 11 antibody-associated encephalitis: Two case reports and review of the literatureAlejandro León Betancourt, Anina Schwarzwald, Alban Millonig, et al.
CNS Neuroscience & Therapeutics|August 17, 2022
Multidimensional phenotyping of the post-COVID-19 syndrome: A Swiss survey studyLara Diem, Anina Schwarzwald, Christoph Friedli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 6, 2025
Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?Gabriel Bsteh, Stefanie Marti, Helly Hammer, et al.
Acta Neuropathologica Communications|June 18, 2026
Higher disease reactivation risk in women after fingolimod withdrawalMarine Massy, Stefanie Marti, Adriane Kutllovci, et al.
Journal of Central Nervous System Disease|May 7, 2024
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational studyChristoph Friedli, Nik Krajnc, Helly N Hammer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 8, 2016
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathyRobert Hoepner, Eva M Kolb, Stefanie Dahlhaus, et al.
Multiple Sclerosis and Related Disorders|December 11, 2024
Disability progression is a question of definition-A methodological reappraisal by example of primary progressive multiple sclerosisGabriel Bsteh, Stefanie Marti, Nik Krajnc, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2021
Different Fumaric Acid Esters Elicit Distinct Pharmacologic ResponsesBrian T Wipke, Robert Hoepner, Katrin Strassburger-Krogias, et al.
Frontiers in Digital Health|June 15, 2026
Listening to MS: AI-assisted speech analysis for diagnosis and fatigue prediction (COMMITMENT)Helly Hammer, Monica Gonzalez-Machorro, Pascal Hecker, et al.
Pageof 13